REAL-TIME & REAL-CONDITION CHARACTERIZATION OF ADJUVANTS AND VACCINES
½Ç ½Ã°£À¸·Î ½ÇÁ¦ ¶Ç´Â °¡¼Ó Á¶°Ç¿¡¼ ºÐ»ê ¾ÈÁ¤¼ºÀ» ÃøÁ¤ÇÏ´Â ºÐ¼® ±â±â¡¯¸¦ Á¦°øÇÏ´Â µ¶ÀÏ LUM»çÀÇ À¥ ¼¼¹Ì³ª°¡ ÃÖ±Ù ÁøÇàµÇ¾ú½À´Ï´Ù. ¼¼¹Ì³ª ³»¿ë Áß, LUM»ç°¡ °ø±ÞÇÏ´Â Àåºñ Áß¿¡ ÇϳªÀÎ LUMiReader PSA¸¦ »ç¿ëÇÑ vaccine adjuvants °ü·Ã case study¸¦ ¼Ò°³ÇÕ´Ï´Ù.
2011³â¿¡ ÀÛ¼ºµÈ WHO Technical Report Series 962, WHO Expert Committee on Biological Standardization Fifty-seventh repor (Annex 3)¿¡ ¡®Guidelines on stability evaluation of vaccines¡¯ÀÌ
Æ÷ÇԵǾî ÀÖÀ¸¸ç ´ÙÀ½ ³»¿ëÀ» ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù:
(1) ¹é½ÅÀÇ »ý»ê°ú »ç¿ëÀÇ °¢ ´Ü°è¿¡¼ ¾ÈÁ¤¼º Æò°¡,
(2) ¹é½ÅÀÇ ¾ÈÁ¤¼º Æò°¡¿Í °ü·ÃµÈ ±ÔÁ¦ »çÇ×,
(3) ½ÇÇè °èȹ°ú Åë°èÀû °í·Á »çÇ×,
(4) µ¥ÀÌÅÍ ºÐ¼®,
(5) combined vaccinesÀÇ ¾ÈÁ¤¼º Æò°¡,
(6) label ¹æ¹ý.
Accelerated stability studies
À§ÀÇ ³»¿ë Áß accelerated (°¡¼ÓÈ) stability studies¿¡ ´ëÇÑ ³»¿ëÀ» »ìÆ캸¸é, Àå±âÀûÀÎ ¾ÈÁ¤¼ºÀ»ÆÇ´ÜÇϱâ À§Çؼ accelerated degradation testÀÇ µ¥ÀÌÅ͸¦ È°¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ ±Ç°í ÀúÀå ¿Âµµº¸´Ù ³ôÀº ¿Âµµ¿¡ ³ëÃâµÈ °á°ú·Î½á ÀÏÁ¤ ½Ã°£ µ¿¾È ¹é½ÅÀÇ Ç°Áú º¯ÈÀ²À» °áÁ¤ÇÏ´Â ¿¬±¸°¡ °¡´ÉÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ ¿¬±¸´Â Ãʱ⠰³¹ß ´Ü°è¿¡¼ ¹é½ÅÀÇ ¾ÈÁ¤¼º¿¡ ´ëÇÑ
preliminary informationÀ» Á¦°øÇÏ°í »ý»ê °øÁ¤ º¯È ÈÄ ¹é½ÅÀÇ ¾ÈÁ¤¼ºÀ» Æò°¡Çϴµ¥ È°¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ¿¬±¸´Â À¯Åë±âÇÑÀ̳ª Ãâ½Ã»ç¾çÀ» ¼³Á¤Çϴµ¥ support data·Î »ç¿ëµÉ ¼ö ÀÖÁö¸¸,
¹é½ÅÀÇ real-time & real-condition stability¸¦ ¿¹ÃøÇϴµ¥ »ç¿ëµÇ¾î¼´Â ¾ÈµË´Ï´Ù.
Real-time & real-condition stability study of formulations with Al-adjuvants
¿¹»ó °ü¸®/ÀúÀå Á¶°Ç¿¡¼ ¿¹»ó À¯Åë/ÀúÀå ±â°£µ¿¾È ¹é½ÅÀÇ ¹°¸®ÇÐÀû, ÈÇÐÀû, »ý¹°ÇÐÀû, »ý¹°¾àÁ¦ÇÐÀû, ¹Ì»ý¹°ÇÐÀû Ư¼º¿¡ ´ëÇÑ ½Ç½Ã°£ & ½ÇÁ¶°Ç ¾ÈÁ¤¼º¿¡ ´ëÇÑ ¿¬±¸´Â ÀúÀå Á¶°ÇÀ» Á¦¾ÈÇÏ°í
À¯Åë±âÇÑ°ú Ãâ½Ã»ç¾çÀ» ¼³Á¤Çϱâ À§ÇØ »ç¿ëµË´Ï´Ù.
À¥ ¼¼¹Ì³ª¿¡¼´Â aluminum adjuvantsÀÇ ½Ç½Ã°£ & ½ÇÁ¶°Ç ¾ÈÁ¤¼º ¿¬±¸ »ç·Ê°¡ ¼Ò°³µÇ¾ú½À´Ï´Ù.
½ÇÇè 1: Different redispersing of one sample
Al(OH)3¿¡ proteinÀ» loadÇÏÁö ¾ÊÀº Placebo »ùÇÃÀ» ÃøÁ¤ Àü¿¡ 2°¡Áö Á¶°ÇÀÇ °µµ·Î shakingÇÏ¿© ÁغñÇÏ¿´½À´Ï´Ù: ¾àÇÏ°Ô redispersing (S), °ÇÏ°Ô redispersing (R).
¾Æ·¡ LUMiReader PSA ÃøÁ¤ °á°ú¸¦ º¸½Ã¸é shaking °µµ¿¡ µû¶ó ´Ù¸£°Ô ħ°ÇÑ °ÍÀ» º¼ ¼ö ÀÖ½À´Ï´Ù. »ùÇà RÀº ÀÔÀÚÀÇ Ä§Àü ¼Óµµ°¡ »ó´ëÀûÀ¸·Î ´õ ´À¸®°Ô ³ªÅ¸³µÀ¸¸ç,
»ùÇà S´Â »ó´ëÀûÀ¸·Î ħÀü ¼Óµµ°¡ ºü¸£°Ô ³ªÅ¸³µ½À´Ï´Ù. S´Â ¿©ÀüÈ÷ ÀÀÁýü°¡ ÀÖ¾úÀ¸³ª, RÀº °ÇÑ shakingÀ¸·Î ÀÎÇØ ÀÀÁýü°¡ Æı«µÈ °ÍÀ» ¾Ë ¼ö ÀÖ¾ú½À´Ï´Ù.
ÀÌ °á°ú´Â µ¶ÀÏ LUM»çÀÇ ºÐ»ê¾ÈÁ¤¼º ÃøÁ¤ ±â±âÀÎ LUMiReader PSA¸¦ »ç¿ëÇÏ¿´À» ¶§ energy entry°¡ »ùÇÿ¡ ÁÖ´Â ¿µÇâ°ú re-dispersibilityÀÇ Á¤µµ¸¦ ÃøÁ¤ÇÒ ¼ö ÀÖÀ½À» º¸¿©ÁÖ´Â °ÍÀ̾ú½À´Ï´Ù.
½ÇÇè 2: Repeated redispersing of one sample with same intensity
¸ÕÀú Al(OH)3¿¡ proteinÀ» high loadingÇÑ »ùÇÃÀ» ÁغñÇÏ¿´½À´Ï´Ù. ÀÌ »ùÇÃÀ» ¸ðµÎ ¾àÇÑ °µµ·Î µ¿ÀÏÇÏ°Ô shaking ÇØÁÖ°í ÀÌ »ùÇõéÀÇ ºÐ»ê ¾ÈÁ¤¼ºÀ» LUMiReader PSA·Î ÃøÁ¤ÇÏ¿´½À´Ï´Ù.
ÀÌ¿Í °°Àº ¹Ýº¹ ½ÇÇèÀ¸·Î ÀÌ ±â±â¸¦ ÅëÇØ ÀçÇö °¡´ÉÇÑ ºÐ»ê ¾ÈÁ¤¼º ºÐ¼® °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´ÂÁö ¾Ë¾Æº¸¾Ò½À´Ï´Ù.
¾Æ·¡ ±×·¡ÇÁ¿¡¼ º¼ ¼ö ÀÖ´Â ¹Ù¿Í °°ÀÌ LUM»ç¿¡¼ Á¦°øÇÏ´Â Àü¿ë ¼ÒÇÁÆ®¿þ¾î·Î ºÐ¼®ÇÏ¿´À» ¶§, Á¦°øµÈ ºÐ¼® ¹æ¹ý Áß Front Tracking ºÐ¼® °á°ú¿¡ ÀÇÇØ Ä§° ¼Óµµ¸¦ °áÁ¤ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù.
3ȸ ¹Ýº¹ ½ÇÇè °á°ú´Â À¯ÀÇÀûÀÎ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Æ ÀÌ ±â±âÀÇ ÃøÁ¤ÀÌ ÀçÇö°¡´ÉÇÑ °á°úÀÓÀ» ¾Ë ¼ö ÀÖ¾ú½À´Ï´Ù.
½ÇÇè 3: Sedimentation velocity of three different samples with same redispersing
Al(OH)3¿¡ proteinÀ» loadingÇÏÁö ¾Ê°Å³ª (A), low loading (B), high loading (C) ÇÏ¿©, ÀÌ ¼¼ ½Ã·á¸¦ °¢°¢ ¾àÇÏ°Ô shakingÇÏ¿© redispersed ½ÃÄÑ ÁغñÇÏ¿´½À´Ï´Ù.
¾Æ·¡ ¿ÞÂÊ ±×·¡ÇÁ¸¦ º¸½Ã¸é °¢ formulation ³»ÀÇ Ä§° ÀÔÀÚÀÇ ¼Óµµ°¡ ½Ã·á¸¶´Ù ´Ù¸£°Ô ³ªÅ¸³²À» ¾Ë ¼ö ÀÖ¾úÀ¸¸ç, loaded proteinÀÌ Ä§°¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Á¤·®È ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù.
Summary
Multiwavelength - Separation Anayser - LUMiReader¢ç PSA 452´Â vaccine°ú adjuvants ¿¬±¸¿¡¼ ´ÙÀ½°ú °°ÀÌ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.
WHO guidanceÀÇ ±Ç°í¸¦ µû¸¥ ¡®Real-time & real-condision stability¡¯ ¿¬±¸¿¡¼ ºÐ»ê¾×ÀÇ ¹°¸®ÀûÀΠƯ¼ºÀ»   Á÷Á¢ÀûÀ¸·Î ¾Ë ¼ö ÀÖÀ¸¸ç,
¹°¸®Àû Ư¼º¿¡ ¿µÇâÀ» ÁÖ´Â ¿äÀο¡ ´ëÇÑ Á¤º¸¸¦ °£Á¢ÀûÀ¸·Î ¾Ë ¼ö ÀÖ½À´Ï´Ù.
WHO guidanceÀÇ ±âÁØ¿¡ ºÎÇÕÇÑ Á¶°Ç (4~80¡É)¿¡¼ ¡®Accelerated stability studies¡¯¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù
»ùÇÃÀÇ ¿ø·¡ ³óµµ ¼öÁØ¿¡¼ ºÐ»ê ¾ÈÁ¤¼ºÀ» È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.
±× ¿Ü¿¡µµ ´ÙÀ½°ú °°Àº ´õ ¸¹Àº ¸ñÀûÀ¸·Î LUMiReader¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
|
|
|
LumiSizer Dispersion Analyzer
LumiFuge Stability Analyzer
LumiReader PSA Separation Analyzer
|
|